The present disclosure provides, among other things, compositions and methods useful for inhibiting biofilm-forming bacteria. For example, the compositions and methods described herein can be used to inhibit the proliferation, viability, and/or biofilm-forming activity, of biofilm-forming bacteria.

Mite proteins according to an aspect may be used in diagnosing allergic diseases. Results of diagnosing allergic diseases by using the proteins have high reliability and validity. Further, the proteins may be used in a composition for preventing or treating allergic diseases.

The present invention relates to a composition for improving memory, or a composition for preventing and treating Alzheimer's disease, or a method for preparing said compositions, or a treatment method, wherein said compositions are characterized by comprising a cooked silkworm product and an Angelica root extract as effective components. As the present invention provides compositions using an Angelica root extract and a silkworm product rich in silk proteins and functional materials derived from mulberry leaves to improve memory and prevent or treat Alzheimer's disease, various health supplement products or drugs using the present invention are expected to be developed and commercialized, making it possible to fundamentally prevent and treat aging and dementia associated with aging, which are arising as a major problem in modern societies, and also to provide benefits of memory improvements in various other demographics, such as students, students studying for exams, office workers, etc.

The present invention relates to a bee venom-purifying method comprising a virus clearance process and a composition for preventing or treating inflammatory disease by using same, the method comprising the steps of: (a) preparing a bee venom solution containing bee venom; (b) adjusting the pH of the bee venom solution prepared in step (a) into 2.0 to 4.0 by acid treatment to primarily deactivate viruses; and (c) filtering the pH-adjusted bee venom solution of step (b) through a nanofilter of 10 to 20 nm to secondarily remove viruses.

Nanoparticulate, ion-paired complexes of melittin (MLN) and one or more non-steroidal anti-inflammatory drugs, and particularly MLN ion-paired with diclofenac, provide for enhanced wound healing in humans and other animals. Compositions having the nanonparticulates distributed therein or thereon are applied topically to the wound, and the ion-paired complexes have been shown to demonstrate superior wound healing and closure.

The present invention relates to a pharmaceutical composition for treating wounds, containing a silk protein and a plasma component as active ingredients. According to the present invention, wounds can be more effectively healed by using synergistic effects of a silk protein and a plasma component.

The present invention relates to a pharmaceutical composition for treating wounds, containing a silk protein and a plasma component as active ingredients. According to the present invention, wounds can be more effectively healed by using synergistic effects of a silk protein and a plasma component.

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.

Provided herein are, inter alia, compositions and methods for identifying and using agents capable of inhibiting myofibroblast transition as well as methods for treating diseases associated with the same in a subject in need thereof.